FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling

Journal of Clinical Pharmacology

Volumn 39, Issue 9, 1999, Pages 899-910

  Davit, B ^a   Reynolds, K ^a   Yuan, R ^a   Ajayi, F ^a   Conner, D ^a   Fadiran, E ^a   Gillespie, B ^a   Sahajwalla, C ^a   Huang, S M ^a   Lesko, L J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CYTOCHROME; DIRITHROMYCIN; EPROSARTAN; ERYTHROMYCIN; FEXOFENADINE; FLUCONAZOLE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; GREPAFLOXACIN; INDINAVIR; KETOCONAZOLE; LEUKOTRIENE; LOSARTAN; LOSARTAN POTASSIUM; NELFINAVIR; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PLASMA PROTEIN; RITONAVIR; SAQUINAVIR; TERFENADINE; THEOPHYLLINE; TOPIRAMATE; WARFARIN; ZAFIRLUKAST;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG LABELING; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; PREDICTION AND FORECASTING; REVIEW;

EID: 0033323809     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008515     Document Type: Review

References (76)

1. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: Study design and data analysis issues
2. Warfarin-fluconazole II: Inhibition of human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies
3. Warfarin-fluconazole II: A metabolically based drug interaction: In vivo studies
4. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
5. A fluvoxamine-caffeine interaction study
6. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
7. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers
8. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
9. Prediction of in vivo drug interaction from in vitro systems exemplified by interaction between verapamil and cimetidine using human liver microsomes and primary hepatocytes
10. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
11. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
12. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport
13. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
14. In vitro approaches to predicting drug interactions in vivo
15. Saquinavir: Clinical pharmacology and efficacy
16. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
17. HIV-1 protease inhibitors: A review for clinicians
18. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4
19. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
20. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
21. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors
22. Protease inhibitors as inhibitors of human cytochrome P450: High risk associated with ritonavir
23. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
24. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
25. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
26. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: Major role of CYP3A
27. Role of cytochrome P450 3A in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor
28. Biotransformation of losartan to its carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members
29. Ketoconazole does not affect the systemic conversion of losartan to E-3174
30. Fluconazole, but not itraconazole, decreases the metabolism of losartan to E-3174
31. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
32. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
33. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers
34. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
35. Clinical pharmacokinetics of alprazolam: Therapeutic implications
36. Drug interactions with newer antidepressants: Role of human cytochromes P450
37. Alprazolam is another substrate for human cytochrome P450-3A isoforms
38. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
39. Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men
40. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine
41. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam
42. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways
43. Topiramate, clinical profile in epilepsy
44. Pharmacokinetics and biotransformation studies of terfenadine in man
45. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences
46. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
47. OATP and P-glycoprotein mediate the uptake and excretion of fexofenadine
48. A drug interaction between zafirlukast and theophylline
49. Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics
50. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
51. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoproteinin human cultured cells
52. 14C]saquinavir in normal and P-glycoprotein (P-GP) deficient mice and cultured cells
53. Molecular and physical mechanisms of first-pass extraction
54. Effects of ketoconazole on digoxin absorption and disposition in the rat
55. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-578) in rats, dogs, and humans
56. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir